L575-0675 Screening compound: N-[(4-ethylphenyl)methyl]-4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide

L575-0675 Screening compound: N-[(4-ethylphenyl)methyl]-4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide
L575-0675 Screening compound: N-[(4-ethylphenyl)methyl]-4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L575-0675
N-[(4-ethylphenyl)methyl]-4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L575-0675

Molecular Formula

C25H33N5O4 (C25 H33 N5 O4)

Compound Name

N-[(4-ethylphenyl)methyl]-4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide

IUPAC name

N-[(4-ethylphenyl)methyl]-4-[1-methyl-3-(morpholine-4-carbonyl)-1H4H5H6H7H-pyrazolo[43-c]pyridin-5-yl]-4-oxobutanamide

SMILES

CCc1ccc(CNC(CCC(N(CC2)Cc3c2n(C)nc3C(N2CCOCC2)=O)=O)=O)cc1

InChI

InChI=1S/C25H33N5O4/c1-3-18-4-6-19(7-5-18)16-26-22(31)8-9-23(32)30-11-10-21-20(17-30)24(27-28(21)2)25(33)29-12-14-34-15-13-29/h4-7H,3,8-17H2,1-2H3,(H,26,31)

InChI Key

BJVUXPGBJRWPHX-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27463591

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

467.57

Hydrogen Bond Acceptors Count

8.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

10.00

Number of Nitrogen and Oxygen Atoms

9

Partition Coefficient, logP

0.435

Distribution Coefficient, logD

0.435

Water Solubility, LogSw

-2.04

Polar Surface Area

80.067

Acid Dissociation Constant (pKa)

12.94

Base Dissociation Constant (pKb)

3.55

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

52.00

L575-0675 in Drug Discovery

Included in Screening Libraries

Anticancer Library (62698 compounds)

Cysteine Proteases Inhibitors Library (7839 compounds)

Hsp90-Targeted Library (11355 compounds)

Regenerative Medicine Focused Library (23016 compounds)

Adenosine Receptors Targeted Library (19896 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
  • Musculoskeletal
  • Digestive system
  • Hemic and lymphatic
  • Cardiovascular
  • Skin
  • wounds
  • Cancer
  • Digestive system
  • Respiratory tract
  • Nervous system
  • Eye
  • Cardiovascular
Targets:
  • Proteases
  • GPCR
Mechanism of action:
  • Receptor's ligands

References: we are preparing a list of scientific research reports with L575-0675 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L575-0675?
Check Price and Availability of L575-0675, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L575-0675 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L575-0675
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L575-0675
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L575-0675 available by request